Analogue Analysis in Rare Diseases
A structured scorecard for confident pricing and HTA decisions
Analogue analysis is central to how orphan therapies are positioned, priced and assessed by payers. Yet in rare diseases, selecting the right comparators is rarely straightforward.
This scorecard builds on our article and provides a practical, question-led, framework to structure analogue assessment across multiple dimensions, helping teams move beyond single comparator thinking.
Why download this scorecard
In rare diseases, analogue selection is often inconsistent, difficult to justify, and highly dependent on individual interpretation. Use this scorecard to:
Structure analogue assessment across multiple relevant dimensions
Strengthen justification of pricing and HTA positioning
Make uncertainty explicit and easier to manage
Support more consistent and repeatable decision-making
What's inside?
A ready-to-use analogue scorecard template.
The four key dimensions for structures comparator assessment
Guidance on how to adapt weighting based on your strategic question
An example application to support interpretation and use
This Resource is Essential For: Global Market Access leaders, Pricing and Market Access teams, HEOR and evidence strategy teams, as well as early access and BD teams working on rare disease asset.
Get Your Resource
Are you evaluating a rare disease asset or preparing for launch?
Our specialists support you across early pricing, analogue analysis, evidence strategy and HTA positioning to define a clear access strategy.
Grounded in real-world data and payer insight, we help you reduce uncertainty and move forward with confidence.